Progress in primary aldosteronism: Present challenges and perspectives

Hormone and Metabolic Research

Volumn 42, Issue 6, 2010, Pages 374-381

  Gomez Sanchez, C E ^a   Rossi, G P ^b   Fallo, F ^c   Mannelli, M ^d  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

^d UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Adrenal adenoma; Adrenal cortex; Adrenal tumor; Aldosterone; Mineralocorticoid; Steroidogenesis

Indexed keywords

CAPTOPRIL; SPIRONOLACTONE;

ADRENAL SUPPRESSION; ADRENAL VEIN CATHETERIZATION; ALDOSTERONE BLOOD LEVEL; ALDOSTERONE PRODUCING ADENOMA; ALDOSTERONE RELEASE; ALDOSTERONE RENIN RATIO; ALDOSTERONE SUPPRESSION TEST; CLINICAL FEATURE; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; ENDOCRINE TUMOR; FEASIBILITY STUDY; HUMAN; HYPERTENSION; HYPOKALEMIA; INCIDENCE; MASS SCREENING; NODULAR GOITER; PHEOCHROMOCYTOMA; PLASMA RENIN ACTIVITY; PREVALENCE; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; REPRODUCIBILITY; REVIEW; SALT INTAKE; SENSITIVITY AND SPECIFICITY; VEIN CATHETERIZATION; ZONA GLOMERULOSA;

ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL ADENOMA; ALDOSTERONE; DIAGNOSIS, DIFFERENTIAL; ENDOCRINOLOGY; GOITER, NODULAR; HUMANS; HYPERALDOSTERONISM; RENIN;

EID: 77952895143     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0029-1243619     Document Type: Review

References (104)

1. Conn JW. Primary aldosteronism, a new clinical syndrome. J Lab Clin Med 1955 45 3-7
2. Conn JW, Knopf RF, Nesbit RM. Clinical characteristics of primary aldosteronism from an analysis of 145 cases. Am J Surg 1964 107 159-172
3. Conn JW, Cohen EL, Rovner DR, Nesbit RM. Normokalemic primary aldosteronism. A detectable cause of curable essential hypertension. JAMA 1965 193 200-206
4. Andersen GS, Toftdahl DB, Lund JO, Strandgaard S, Nielsen PE. The incidence rate of phaeochromocytoma and Conns syndrome in Denmark, 19771981. J Hum Hypertens 1988 2 187-189
5. Kaplan NM. Hypokalemia in the hypertensive patient, with observations on the incidence of primary aldosteronism. Ann Int Med 1967 66 1079-1090
6. Holland O, Brown H, Kuhnert L, Fairchild C, Risk M, Gomez-Sanchez CE. Further evaluation of saline infusion for the diagnosis of primary aldosteronism. Hypertension 1984 6 717-723
7. Gordon RD, Stowasser M, Tunny TJ, Klemm SA, Rutherford JC. High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin Expt Pharmacol Physiol 1994 21 315-318
8. Anderson GH Jr, Blakeman N, Streeten DH. The effect of age on prevalence of secondary forms of hypertension in 4429 consecutively referred patients. J Hypertension 1994 12 609-615
9. Loh KC, Koay ES, Khaw MC, Emmanuel SC, Young WF. Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. J Clin Endocrinol Metab 2000 85 2854-2859
10. Fardella CE, Mosso L, Gomez-Sanchez CE, Soto J, Montero J, Gomez L, Pinto M, Oestreicher E, Corts P. Primary hyperaldosteronism in essential hypertensives: Prevalence, biochemical profile and molecular biology. J Clin Endocrinol Metab 2000 85 1863-1867
11. Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 2002 40 892-896
12. Plouin PF, Amar L, Chatellier G, Gosse P, Tabarin A, Reznik Y, Baguet JP, Chabre O, Prost A, Wemeau JL, Berthezene F, Fauvel JP, Milon H, Vincent M, Conte-Devolx B, Bertagna X, Mouradian D, Herpin D, Croisier-Lukas C, Lefebvre H, Imbs JL, Chamontin B. Trends in the prevalence of primary aldosteronism, aldosterone-producing adenomas, and surgically correctable aldosterone-dependent hypertension. Nephrol Dial Transpl 2004 19 774-777
13. Mulatero P, Stowasser M, Loh KC, Fardella CE, Gordon RD, Mosso L, Gomez-Sanchez CE, Veglio F, Young WF Jr. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab 2004 89 1045-1050
14. Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, Ganzaroli C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Mattarello MJ, Moretti A, Palumbo G, Parenti G, Porteri E, Semplicini A, Rizzoni D, Rossi E, Boscaro M, Pessina AC, Mantero F. A prospective study of the prevalence of primary aldosteronism in 1125 hypertensive patients. J Am Coll Cardiol 2006 48 2293-2300
15. Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, Young WF Jr, Montori VM. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008 93 3266-3281
16. Abdelhamid S, Blomer R, Hommel G, Haack D, Lewicka S, Fiegel P, Krumme B. Urinary tetrahydroaldosterone as a screening method for primary aldosteronism: a comparative study. Am J Hypertens 2003 16 522-530
17. Weinberger MH, Grim CE, Hollifield JW, Kem DC, Ganguly A, Kramer NJ, Yune HY, Wellman H, Donohue JP. Primary aldosteronism: diagnosis, localization, and treatment. Ann Intern Med 1979 90 386-395
18. Rodriguez JA, Lopez JM, Biglieri EG. DOCA test for aldosteronism: its usefulness and implications. Hypertension 1981 3 II-102
19. Anderson GH, Blakeman N, Streeten DHP. The effect of age on prevalence of secondary forms of hypertension in 4429 consecutively referred patients. J Hypertension 1994 12 609-615
20. Flood C, Layne DS, Ramcharan S, Rossipal E, Tait JF, Tait SA. An investigation of the urinary metabolites and secretion rates of aldosterone and cortisol in man and a description of methods for their measurement. Acta Endocrinol (Copenh) 1961 36 237-264
21. Hiramatsu K, Yamada T, Yukimura Y, Komiya I, Ichikawa M, Nagata H, Izumiyama T. A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Results in hypertensive patients. Arch Intern Med 1981 141 1589-1593
22. Born-Frontsberg E, Reincke M, Beuschlein F, Quinkler M. Tumor size of Conn's adenoma and comorbidities. Horm Metab Res 2009 41 785-788
23. Rossi GP, Sacchetto A, Pavan E, Scognamiglio R, Pietra M, Pessina AC. Left ventricular systolic function in primary aldosteronism and hypertension. J Hypertension 1998 16 2075-2077
24. Rossi GP, Di Bello V, Ganzaroli C, Sacchetto A, Cesari M, Bertini A, Giorgi D, Scognamiglio R, Mariani M, Pessina AC. Excess aldosterone is associated with alterations of myocardial texture in primary aldosteronism. Hypertension 2002 40 23-27
25. Rossi GP. Cardiac consequences of aldosterone excess in human hypertension. Am J Hypertens 2006 19 10-12
26. Rossi GP, Bernini G, Desideri G, Fabris B, Ferri C, Giacchetti G, Letizia C, Maccario M, Mannelli M, Matterello MJ, Montemurro D, Palumbo G, Rizzoni D, Rossi E, Pessina AC, Mantero F. Renal damage in primary aldosteronism: results of the PAPY Study. Hypertension 2006 48 232-238
27. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005 45 1243-1248
28. Catena C, Colussi G, Nadalini E, Chiuch A, Baroselli S, Lapenna R, Sechi LA. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med 2008 168 80-85
29. Montori VM, Young WF Jr. Use of plasma aldosterone concentration-to- plasma renin activity ratio as a screening test for primary aldosteronism. A systematic review of the literature. Endocrinol Metab Clin North Am 2002 31 619-632, xi
30. Stowasser M, Gordon RD. Primary aldosteronism careful investigation is essential and rewarding. Mol Cell Endocrinol 2004 217 33-39
31. Mulatero P, Rabbia F, Milan A, Paglieri C, Morello F, Chiandussi L, Veglio F. Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. Hypertension 2002 40 897-902
32. Lim PO, Jung RT, MacDonald TM. Raised aldosterone to renin ratio predicts antihypertensive efficacy of spironolactone: a prospective cohort follow-up study. Br J Clin Pharmacol 1999 48 756-760
33. Bravo EL, Tarazi RC, Dustan HP, Fouad FM, Textur SC, Gifford RW, Vidt DG. The changing clinical spectrum of primary aldosteronism. Am J Med 1983 74 641-651
34. Kem DC, Weinberger MH, Gomez-Sanchez CE, Kramer NJ, Lerman R, Ferman R, Furuyama S, Nugent CA. Circadian rhythms of plasma aldosterone concentration in normal subjects and patients with primary aldosteronism. J Clin Invest 1973 52 2272-2277
35. Weinberger MH, Kem DC, Gomez-Sanchez CE, Kramer NJ, Martin BT, Nugent CA. The role of renin, ACTH, and potassium in the control of episodic variation of plasma aldosterone concentration in normal, recumbent humans. Res Steroids 1975 6 35-48
36. Kem DC, Weinberger MH, Gomez-Sanchez CE, Higgins JR, Kramer NJ. The role of ACTH in the episodic release of aldosterone in patients with idiopathic adrenal hyperplasia, hypertension, and hyperaldosteronism. J Lab Clin Med 1976 88 261-270
37. Rossi GP, Seccia TM, Palumbo G, Belfiore A, Bernini G, Caridi G, Desideri G, Fabris B, Ferri C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Patalano A, Rizzoni D, Rossi E, Pessina A, Mantero F. Within-patient Reproducibility of the Aldosterone/Renin Ratio (ARR) in Primary Aldosteronism. Hypertension 2009 Nov 23 [Epub ahead of print]
38. Ferrari P, Shaw SG, Nicod J, Saner E, Nussberger J. Active renin versus plasma renin activity to define aldosterone-to-renin ratio for primary aldosteronism. J Hypertens 2004 22 377-381
39. Young WF, Stanson AW, Thompson GB, Grant CS, Farley DR, van Heerden JA. Role for adrenal venous sampling in primary aldosteronism. Surgery 2004 136 1227-1235
40. Streeten DHP, Tomycz N, Anderson GH. Reliability of screening methods for the diagnosis of primary aldosteronism. Am J Med 1979 67 403-413
41. Gordon RD, Gomez-Sanchez CE, Hamlet SM, Tunny TJ, Klemm SA. Angiotensin-responsive aldosterone-producing adenoma masquerades as idiopathic hyperaldosteronism (IHA: adrenal hyperplasia) or low-renin essential hypertension. J Hypertens Suppl 1987 5 S103-S106
42. Irony I, Kater CE, Biglieri EG, Shackleton CH. Correctable subsets of primary aldosteronism. Primary adrenal hyperplasia and renin responsive adenoma. Am J Hypertens 1990 3 576-582
43. Phillips JL, Walther MM, Pezzullo JC, Rayford W, Choyke PL, Berman AA, Linehan WM, Doppman JL, Gill JR Jr. Predictive value of preoperative tests in discriminating bilateral adrenal hyperplasia from an aldosterone producing adrenal adenoma. J Clin Endocrinol Metab 2000 85 4526-4533
44. Rossi GP, Belfiore A, Bernini G, Desideri G, Fabris B, Ferri C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Montemurro D, Palumbo G, Rizzoni D, Rossi E, Semplicini A, Agabiti-Rosei E, Pessina AC, Mantero F. Prospective evaluation of the saline infusion test for excluding primary aldosteronism due to aldosterone-producing adenoma. J Hypertens 2007 25 1433-1442 (Pubitemid 46918831)
45. Rossi GP, Belfiore A, Bernini G, Desideri G, Fabris B, Ferri C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Palumbo G, Rizzoni D, Rossi E, Agabiti-Rosei E, Pessina AC, Mantero F. Comparison of the captopril and the saline infusion test for excluding aldosterone-producing adenoma. Hypertension 2007 50 424-431 (Pubitemid 47205795)
46. Letavernier E, Peyrard S, Amar L, Zinzindohoue F, Fiquet B, Plouin PF. Blood pressure outcome of adrenalectomy in patients with primary hyperaldosteronism with or without unilateral adenoma. J Hypertens 2008 26 1816-1823
47. Ferriss JB, Beevers DG, Brown JJ, Fraser R, Lever AF, Padfield PL, Robertson JI. Low-renin (primary) hyperaldosteronism. Differential diagnosis and distinction of sub-groups within the syndrome. Am Heart J 1978 95 641-658
48. Connell JM, MacKenzie SM, Freel EM, Fraser R, Davies E. A lifetime of aldosterone excess: long-term consequences of altered regulation of aldosterone production for cardiovascular function. Endocr Rev 2008 29 133-154
49. Padfield PL, Brown JJ, Davies D, Fraser R, Lever AF, Morton JJ, Robertson JI. The myth of idiopathic hyperaldosteronism. Lancet 1981 2 83-84
50. Padfield PL, Brown JJ, Lever AF, Schalekamp MA, Beevers DG, Davies DL, Robertson JI, Tree M. Is low-renin hypertension a stage in the development of essential hypertension or a diagnostic entity? Lancet 1975 1 548-550
51. Biglieri EG, Schambelan M, Slaton PE, Stockigt JR. The intercurrent hypertension of primary aldosteronism. Circ Res 1970 26/27 (Suppl I) I195-I202
52. Spark RF, Melby JC. Aldosteronism in hypertension. The spironolactone response test. Ann Int Med 1968 69 685-691
53. Plouin PF, Jeunemaitre X. Would wider screening for primary aldosteronism give any health benefits? Eur J Endocrinol 2004 151 305-308
54. Vasan RS, Evans JC, Larson MG, Wilson PW, Meigs JB, Rifai N, Benjamin EJ, Levy D. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med 2004 351 33-41
55. Newton-Cheh C, Guo CY, Gona P, Larson MG, Benjamin EJ, Wang TJ, Kathiresan S, O'Donnell CJ, Musone SL, Camargo AL, Drake JA, Levy D, Hirschhorn JN, Vasan RS. Clinical and genetic correlates of aldosterone-to-renin ratio and relations to blood pressure in a community sample. Hypertension 2007 49 846-856
56. Helber A, Wambach G, Hummerich W, Bnner G, Meurer KA, Kaufmann W. Evidence for a subgroup of essential hypertensives with non-suppressible excretion of aldosterone during sodium loading. Klin Wochenschr 1980 58 439-447
57. Collins RD, Weinberger MH, Dowdy AJ, Nokes GW, Gonzales CM, Luetscher JA. Abnormally sustained aldosterone secretion during salt loading in patients with various forms of benign hypertension; relation to plasma renin activity. J Clin Invest 1970 49 1415-1426
58. Wambach G, Meiners U, Bonner G, Konrads A, Helber A. Cardiovascular and adrenal sensitivity to angiotensin II in essential hypertension. Klin Wochenschr 1984 62 1097-1101
59. Wisgerhof M, Brown RD, Hogan MJ, Carpenter PC, Edis AJ. The plasma aldosterone response to angiotensin II infusion in aldosterone-producing adenoma and idiopathic hyperaldosteronism. J Clin Endocrinol Metab 1981 52 195-198 (Pubitemid 11183610)
60. Oelkers W, Brown JJ, Fraser R, Lever AF, Morton JJ, Robertson JI. Sensitization of the adrenal cortex to angiotensin II in sodium-deplete man. Circ Res 1974 40 69-77
61. Oelkers W, Schoneshofer M, Schultze G, Brown JJ, Fraser R, Morton JJ, Lever AF, Robertson JI. Effect of prolonged low-dose angiotensin II infusion on the sensitivity of adrenal cortex in man. Circ Res 1975 36 49-56
62. Neville AM, O'Hare MJ. Histopathology of the human adrenal cortex. Clin Endocrinol Metab 1985 14 791-820
63. Neville AM, OHare MJ. The human adrenal cortex, pathology and biology. An integrated approach Heidelberg: Springer-Verlag 1982
64. Lack E. AFIP Atlas of tumor pathology, fourth series, fascicle 8. Tumors of the adrenal glands and extraadrenal paraganglia Washington, DC: ARP Press 2007
65. Enberg U, Volpe C, Hoog A, Wedell A, Farnebo LO, Thoren M, Hamberger B. Postoperative differentiation between unilateral adrenal adenoma and bilateral adrenal hyperplasia in primary aldosteronism by mRNA expression of the gene CY11B2. Eur J Endocrinol 2004 151 73-85
66. Shigematsu K, Kawai K, Irie J, Sakai H, Nakashima O, Iguchi A, Shimamatsu J, Shimamatsu K, Kusaba Y, Takahara O. Analysis of unilateral adrenal hyperplasia with primary aldosteronism from the aspect of messenger ribonucleic acid expression for steroidogenic enzymes: a comparative study with adrenal cortices adhering to aldosterone-producing adenoma. Endocrinology 2006 147 999-1006
67. Shigematsu K, Yamaguchi N, Nakagaki T, Sakai H. A case of unilateral adrenal hyperplasia being difficult to distinguish from aldosterone-producing adenoma. Exp Clin Endocrinol Diabetes 2009 117 124-128
68. Lenzini L, Seccia TM, Aldighieri E, Belloni AS, Bernante P, Giuliani L, Nussdorfer GG, Pessina AC, Rossi GP. Heterogeneity of aldosterone-producing adenomas revealed by a whole transcriptome analysis. Hypertension 2007 50 1106-1113
69. Kem DC, Weinberger MH, Higgins JR, Kramer NJ, Gomez-Sanchez CE, Holland OB. Plasma aldosterone response to ACTH in primary aldosteronism and in patients with low renin hypertension. J Clin Endocrinol Metab 1978 46 552-560
70. Gordon RD, Hamlet SM, Tunny TJ, Klemm SA. Aldosterone-producing adenoma responsive to angiotensin poses problems in diagnosis. Clin Expt Pharm Phys 1987 14 175-179
71. Hamlet SM, Gordon RD, Gomez-Sanchez CE, Tunny TJ, Klemm SA. Adrenal transitional zone steroids, 18-oxo and 18-hydroxycortisol, useful in the diagnosis of primary aldosteronism are ACTH-dependent. Clin Expt Pharm Phys 1988 15 317-322
72. Tunny TJ, Gordon RD, Klemm SA, Cohn D. Histological and biochemical distinctiveness of atypical aldosterone-producing adenomas responsive to upright posture and angiotensin. Clin Endocrinol 1991 34 363-369
73. Stowasser M, Tunny TJ, Klemm SA, Gordon RD. Cortisol production by aldosterone-producing adenomas in vitro. Clin Expt Pharm Phys 1993 20 292-295
74. Tunny TJ, Klemm SA, Stowasser M, Gordon RD. Angiotensin-responsive aldosterone-producing adenomas: postoperative disappearance of aldosterone response to angiotensin. Clin Expt Pharmacol Physiol 1993 20 306-309
75. Biglieri EG, Irony I, Kater CE. Identification and implications of new types of mineralocorticoid hypertension. J Steroid Biochem 1989 32 199-204
76. Fallo F, Barzon L, Biasi F, Altavilla G, Boscaro M, Sonino N. Zona fasciculata-like histotype and aldosterone response to upright posture are not related in aldosterone-producing adenomas. Expt Clin Endo Diabetes 1998 106 74-78
77. Lampron A, Bourdeau I, Oble S, Godbout A, Schurch W, Arjane P, Hamet P, Lacroix A. Regulation of aldosterone secretion by several aberrant receptors including for glucose-dependent insulinotropic peptide in a patient with an aldosteronoma. J Clin Endocrinol Metab 2009 94 750-756
78. Lacroix A, Bourdeau I, Lampron A, Mazzuco TL, Tremblay J, Hamet P. Aberrant G-protein coupled receptor expression in relation to adrenocortical overfunction. Clin Endocrinol (Oxf) 2009 Aug 29 [Epub ahead of print]
79. Ye P, Mariniello B, Mantero F, Shibata H, Rainey WE. G-protein-coupled receptors in aldosterone-producing adenomas: a potential cause of hyperaldosteronism. J Endocrinol 2007 195 39-48
80. Zwermann O, Suttmann Y, Bidlingmaier M, Beuschlein F, Reincke M. Screening for membrane hormone receptor expression in primary aldosteronism. Eur J Endocrinol 2009 160 443-451
81. Willenberg HS, Schinner S, Ansurudeen I. New mechanisms to control aldosterone synthesis. Horm Metab Res 2008 40 435-441
82. Ansurudeen I, Kopprasch S, Ehrhart-Bornstein M, Willenberg HS, Krug AW, Funk RH, Bornstein SR. Vascular-adrenal niche-endothelial cell-mediated sensitization of human adrenocortical cells to angiotensin II. Horm Metab Res 2006 38 476-480
83. Georgopoulos NA, Sykiotis GP, Sgourou A, Papachatzopoulou A, Markou KB, Kyriazopoulou V, Papavassiliou AG, Vagenakis AG. Autonomously functioning thyroid nodules in a former iodine-deficient area commonly harbor gain-of-function mutations in the thyrotropin signaling pathway. Eur J Endocrinol 2003 149 287-292
84. Krohn K, Fuhrer D, Bayer Y, Eszlinger M, Brauer V, Neumann S, Paschke R. Molecular pathogenesis of euthyroid and toxic multinodular goiter. Endocr Rev 2005 26 504-524
85. Davies E, Bonnardeaux A, Plouin PF, Corvol P, Clauser E. Somatic mutations of the angiotensin II (AT1) receptor gene are not present in aldosterone-producing adenoma. J Clin Endocrinol Metab 1997 82 611-615
86. Sachse R, Shao XJ, Rico A, Finckh U, Rolfs A, Reincke M, Hensen J. Absence of angiotensin II type 1 receptor gene mutations in human adrenal tumors. Eur J Endocrinol 1997 137 262-266
87. Rossi GP, Pitter G, Bernante P, Motta R, Feltrin G, Miotto D. Adrenal vein sampling for primary aldosteronism: the assessment of selectivity and lateralization of aldosterone excess baseline and after adrenocorticotropic hormone (ACTH) stimulation. J Hypertens 2008 26 989-997
88. Kline GA, Harvey A, Jones C, Hill MH, So B, Scott-Douglas N, Pasieka JL. Adrenal vein sampling may not be a gold-standard diagnostic test in primary aldosteronism: final diagnosis depends upon which interpretation rule is used. Variable interpretation of adrenal vein sampling. Int Urol Nephrol 2008 40 1035-1043
89. Miotto D, De Toni R, Pitter G, Seccia TM, Motta R, Vincenzi M, Feltrin G, Rossi GP. Impact of accessory hepatic veins on adrenal vein sampling for identification of surgically curable primary aldosteronism. Hypertension 2009 54 885-889
90. Mengozzi G, Rossato D, Bertello C, Garrone C, Milan A, Pagni R, Veglio F, Mulatero P. Rapid cortisol assay during adrenal vein sampling in patients with primary aldosteronism. Clin Chem 2007 53 1968-1971
91. Auchus RJ, Michaelis C, Wians FH Jr, Dolmatch BL, Josephs SC, Trimmer CK, Anderson ME, Nwariaku FE. Rapid cortisol assays improve the success rate of adrenal vein sampling for primary aldosteronism. Ann Surg 2009 249 318-321
92. Carr CE, Cope C, Cohen DL, Fraker DL, Trerotola SO. Comparison of sequential versus simultaneous methods of adrenal venous sampling. J Vasc Interv Radiol 2004 15 1245-1250
93. Shade RE, Grim CE. Suppression of renin and aldosterone by small amounts of DOCA in normal man. J Clin Endocrinol Metab 1975 40 652-658
94. Shamma AH, Goddard JW, Sommers SC. A study of the adrenal status in hypertension. J Chronic Dis 1958 8 587-595
95. Commons RR, Callaway CP. Adenomas of the adrenal cortex. Arch Intern Med 1948 81 37-41
96. Russi S, Blumenthal HT, Gray SH. Small adenomas of the adrenal cortex in hypertension and diabetes. Arch Intern Med 1945 76 284-291
97. Kokko JP, Brown TC, Berman MM. Adrenal adenoma and hypertension. Lancet 1967 1 468-470
98. Diaz-Cano S, de Miguel M, Blanes A, Tashjiam R, Galera H, Wolfe H. Clonality as expression of distinctive cell kinetics patterns in nodular hyperplasias and adenomas of the adrenal cortex. Am J Pathol 2000 156 311-319
99. Romero DG, Yanes LL, de Rodriguez AF, Plonczynski MW, Welsh BL, Reckelhoff JF, Gomez-Sanchez EP, Gomez-Sanchez CE. Disabled-2 is expressed in adrenal zona glomerulosa and is involved in aldosterone secretion. Endocrinology 2007 148 2644-2652
100. Shigematsu K, Nakagaki T, Yamaguchi N, Kawai K, Sakai H, Takahara O. Analysis of mRNA expression for steroidogenic enzymes in the remaining adrenal cortices attached to adrenocortical adenomas. Eur J Endocrinol 2008 158 867-878
101. Rossi GP, Bolognesi M, Rizzoni D, Seccia TM, Piva A, Porteri E, Tiberio GA, Giulini SM, Agabiti-Rosei E, Pessina AC. Vascular remodeling and duration of hypertension predict outcome of adrenalectomy in primary aldosteronism patients. Hypertension 2008 51 1366-1371
102. Sawka AM, Young WF, Thompson GB, Grant CS, Farley DR, Leibson C, van Heerden JA. Primary aldosteronism: factors associated with normalization of blood pressure after surgery. Ann Intern Med 2001 135 258-261
103. Rutherford JC, Taylor WL, Stowasser M, Gordon RD. Success of surgery for primary aldosteronism judged by residual autonomous aldosterone production. World J Surg 1998 22 1243-1245
104. Sukor N, Gordon RD, Ku YK, Jones M, Stowasser M. Role of unilateral adrenalectomy in bilateral primary aldosteronism: a 22-year single center experience. J Clin Endocrinol Metab 2009 94 2437-2445